$504 Million is the total value of GREAT POINT PARTNERS LLC's 39 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 65.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXDX | Sell | IGNYTA INC | $26,413,000 | +24.6% | 3,071,300 | -23.2% | 5.25% | +20.5% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $24,248,000 | -16.5% | 560,000 | -25.3% | 4.82% | -19.2% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $21,450,000 | +8.9% | 301,809 | -21.7% | 4.26% | +5.3% |
| AVXS | Sell | AVEXIS INC | $15,206,000 | -22.9% | 200,000 | -51.6% | 3.02% | -25.5% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $11,055,000 | -23.5% | 300,000 | -70.0% | 2.20% | -26.0% |
| TRVN | Sell | TREVENA INC | $1,242,000 | -93.0% | 338,292 | -88.7% | 0.25% | -93.2% |
| ARDMQ | Sell | ARADIGM CORP | $988,000 | -22.0% | 637,279 | -19.5% | 0.20% | -24.6% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $590,000 | -69.7% | 11,517 | -77.8% | 0.12% | -70.7% |
| OPHT | Exit | OPHTHOTECH CORPcall | $0 | – | -7,100 | -100.0% | -0.01% | – |
| CATB | Exit | CATABASIS PHARMACEUTICALS INC | $0 | – | -556,537 | -100.0% | -0.41% | – |
| TENX | Exit | TENAX THERAPEUTICS INC | $0 | – | -1,108,593 | -100.0% | -0.44% | – |
| ALIM | Exit | ALIMERA SCIENCES INC | $0 | – | -2,293,675 | -100.0% | -0.51% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALScall | $0 | – | -500,000 | -100.0% | -0.65% | – |
| DERM | Exit | DERMIRA INC | $0 | – | -114,080 | -100.0% | -0.71% | – |
| OCRX | Exit | OCERA THERAPEUTICS INC | $0 | – | -1,963,777 | -100.0% | -0.85% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -870,261 | -100.0% | -0.85% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALSput | $0 | – | -725,000 | -100.0% | -0.94% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -270,000 | -100.0% | -1.60% | – |
| ITEK | Exit | INOTEK PHARMACEUTICALS CORP | $0 | – | -1,500,000 | -100.0% | -1.88% | – |
| CLCD | Exit | COLUCID PHARMACEUTICALS INC | $0 | – | -437,865 | -100.0% | -3.27% | – |
| MACK | Exit | MERRIMACK PHARMACEUTICALS INC | $0 | – | -5,000,000 | -100.0% | -4.19% | – |
| MDCO | Exit | MEDICINES COput | $0 | – | -750,000 | -100.0% | -5.23% | – |
| ENTA | Exit | ENANTA PHARMACEUTICALS INC | $0 | – | -828,253 | -100.0% | -5.70% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-06-05 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.